RECRUITING

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer

Talk to us

Conditions

Inflammatory Breast CarcinomaInvasive Breast CarcinomaSecond Primary Malignant Neoplasm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.

Official Title

Inflammatory Breast Cancer (IBC) Registry

Quick Facts

Study Start:2007-04-17
Study Completion:2030-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00477100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only).
  2. * Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis.
  3. * Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) \[Cohort I\] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only)
  4. * Age \> 18 years
  5. * Able to provide informed consent
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Jie Willey
CONTACT
713-792-3965
jwilley@mdanderson.org

Principal Investigator

VIcente Valero, MD
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

Banner - MD Anderson Cancer Center
Gilbert, Arizona, 85234
United States
Scripps - MD Anderson Cancer Center
La Jolla, California, 92037
United States
Banner - MD Anderson Cancer Center - Northern Colorado
Greeley, Colorado, 80631
United States
Baptist - MD Anderson Cancer Center
Jacksonville, Florida, 32207
United States
Covenant Medical Center
Saginaw, Michigan, 48604
United States
M D Anderson Cancer Center
Houston, Texas, 77030
United States
MD Anderson in Katy
Houston, Texas, 77094
United States
MD Anderson League City
Nassau Bay, Texas, 77058
United States
MD Anderson in Sugar Land
Sugar Land, Texas, 77478
United States
MD Anderson in The Woodlands
The Woodlands, Texas, 77384
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • VIcente Valero, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2007-04-17
Study Completion Date2030-04-30

Study Record Updates

Study Start Date2007-04-17
Study Completion Date2030-04-30

Terms related to this study

Additional Relevant MeSH Terms

  • Inflammatory Breast Carcinoma
  • Invasive Breast Carcinoma
  • Second Primary Malignant Neoplasm